Encouraged by the results obtained with TRAIL–CDK9i thus far, including on intrinsically chemotherapy-resistant PDAC (Fig. 2a–e), we next enquired whether this combination therapy may afford the opportunity to effectively kill cancers resistant to current therapies and, if so, how broadly this may apply. Here, TNFSF10 is linked to cancer.